in the news
China Business Law Journal: Luzhu Biotechnology Launches HKD341m IPO via Chapter 18AMay 10, 2023
O’Melveny represented Beijing Luzhu Biotechnology Co., Ltd. in its initial public offering and listing of H shares on the Main Board of the Hong Kong Stock Exchange. The IPO offering size was approximately HK$340 million (approximately US$43 million) and is the first Hong Kong IPO of a 18A biotech company in 2023. An O'Melveny team led by Ke Zhu and Ke Geng advised Luzhu Biotech on both US and Hong Kong laws.
Read the full article here.